Household Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 From Adult Index Cases With and Without Human Immunodeficiency Virus in South Africa, 2020-2021: A Case-Ascertained, Prospective, Observational Household Transmission Study.
COVID-19
HIV
SARS-CoV-2
acquisition
transmission
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
08 02 2023
08 02 2023
Historique:
received:
11
04
2022
pubmed:
5
8
2022
medline:
11
2
2023
entrez:
4
8
2022
Statut:
ppublish
Résumé
In South Africa, 19% of adults are living with human immunodeficiency virus (HIV; LWH). Few data on the influence of HIV on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) household transmission are available. We performed a case-ascertained, prospective household transmission study of symptomatic adult index SARS-CoV-2 cases LWH and not living with HIV (NLWH) and their contacts from October 2020 to September 2021. Households were followed up 3 times a week for 6 weeks to collect nasal swabs for SARS-CoV-2 testing. We estimated household cumulative infection risk (HCIR) and duration of SARS-CoV-2 positivity (at a cycle threshold value <30 as proxy for high viral load). HCIR was 59% (220 of 373), not differing by index HIV status (60% LWH vs 58% NLWH). HCIR increased with index case age (35-59 years: adjusted OR [aOR], 3.4; 95% CI, 1.5-7.8 and ≥60 years: aOR, 3.1; 95% CI, 1.0-10.1) compared with 18-34 years and with contacts' age, 13-17 years (aOR, 7.1; 95% CI, 1.5-33.9) and 18-34 years (aOR, 4.4; 95% CI, 1.0-18.4) compared with <5 years. Mean positivity was longer in cases LWH (adjusted hazard ratio, 0.4; 95% CI, .1-.9). Index HIV status was not associated with higher HCIR, but cases LWH had longer positivity duration. Adults aged >35 years were more likely to transmit and individuals aged 13-34 to be infected SARS-CoV-2 in the household. As HIV infection may increase transmission, health services must maintain HIV testing and antiretroviral therapy initiation.
Sections du résumé
BACKGROUND
In South Africa, 19% of adults are living with human immunodeficiency virus (HIV; LWH). Few data on the influence of HIV on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) household transmission are available.
METHODS
We performed a case-ascertained, prospective household transmission study of symptomatic adult index SARS-CoV-2 cases LWH and not living with HIV (NLWH) and their contacts from October 2020 to September 2021. Households were followed up 3 times a week for 6 weeks to collect nasal swabs for SARS-CoV-2 testing. We estimated household cumulative infection risk (HCIR) and duration of SARS-CoV-2 positivity (at a cycle threshold value <30 as proxy for high viral load).
RESULTS
HCIR was 59% (220 of 373), not differing by index HIV status (60% LWH vs 58% NLWH). HCIR increased with index case age (35-59 years: adjusted OR [aOR], 3.4; 95% CI, 1.5-7.8 and ≥60 years: aOR, 3.1; 95% CI, 1.0-10.1) compared with 18-34 years and with contacts' age, 13-17 years (aOR, 7.1; 95% CI, 1.5-33.9) and 18-34 years (aOR, 4.4; 95% CI, 1.0-18.4) compared with <5 years. Mean positivity was longer in cases LWH (adjusted hazard ratio, 0.4; 95% CI, .1-.9).
CONCLUSIONS
Index HIV status was not associated with higher HCIR, but cases LWH had longer positivity duration. Adults aged >35 years were more likely to transmit and individuals aged 13-34 to be infected SARS-CoV-2 in the household. As HIV infection may increase transmission, health services must maintain HIV testing and antiretroviral therapy initiation.
Identifiants
pubmed: 35925613
pii: 6655792
doi: 10.1093/cid/ciac640
pmc: PMC9384657
doi:
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e71-e81Subventions
Organisme : Wellcome Trust
ID : 221003/Z/20/Z
Pays : United Kingdom
Organisme : US Centers for Disease Control and Prevention
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest. C. C. has received grant support from Sanofi Pasteur, the CDC, Wellcome Trust, Programme for Applied Technologies in Health, Bill & Melinda Gates Foundation, and South African Medical Research Council. N. W., A. v. G., J. K., and S. W. report receiving grant funds paid to institution from Sanofi Pasteur and the Bill & Melinda Gates Foundation. A. v. G. also reports an unpaid position as chairperson of the National Advisory Group on Immunisation. L. L. reports receiving grant funds from the CDC and Bill & Melinda Gates Foundation. N. M. reports receiving grant funds paid to institution from Pfizer to conduct observational studies on the burden of pneumonia in South Africa; unpaid participation on a data and safety monitoring board of a tuberculosis (TB) host-directed therapies trial and a scientific advisory board on a trial of an electronic reminder to take daily TB treatment; and an unpaid leadership or fiduciary role with the Setshaba Research Center. S. W. reports an unpaid leadership or fiduciary role for a board, society, committee, or advocacy group. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Références
Nat Med. 2021 Apr;27(4):622-625
pubmed: 33654292
JAMA Netw Open. 2021 Feb 1;4(2):e2037069
pubmed: 33533933
JAMA Netw Open. 2022 Apr 1;5(4):e229317
pubmed: 35482308
Lancet Infect Dis. 2021 May;21(5):629-636
pubmed: 33545090
Front Public Health. 2021 Mar 19;9:652842
pubmed: 33816427
Clin Infect Dis. 2022 Aug 24;75(1):e144-e156
pubmed: 35134129
J Formos Med Assoc. 2021 Jun;120 Suppl 1:S38-S45
pubmed: 33994234
Lancet HIV. 2021 May;8(5):e294-e305
pubmed: 33915101
Lancet Infect Dis. 2020 Oct;20(10):1141-1150
pubmed: 32562601
Medicine (Baltimore). 2021 Jul 2;100(26):e26573
pubmed: 34190201
Euro Surveill. 2020 Aug;25(32):
pubmed: 32794447
PLoS One. 2021 Jul 21;16(7):e0254994
pubmed: 34288954
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Clin Infect Dis. 2022 Aug 24;75(1):e1046-e1053
pubmed: 34791096
Sci Rep. 2021 Mar 18;11(1):6283
pubmed: 33737527
Lancet HIV. 2021 Sep;8(9):e554-e567
pubmed: 34363789
Lancet HIV. 2021 Mar;8(3):e158-e165
pubmed: 33549166
Emerg Infect Dis. 2021 Dec;27(12):3020-3029
pubmed: 34477548
Lancet. 2022 Jan 29;399(10323):437-446
pubmed: 35065011
PLoS One. 2021 Mar 24;16(3):e0243042
pubmed: 33760808
Lancet Infect Dis. 2022 Jun;22(6):821-834
pubmed: 35298900
Lancet HIV. 2021 Jun;8(6):e334-e341
pubmed: 33933189
Influenza Other Respir Viruses. 2022 Jan;16(1):48-55
pubmed: 34378341
Sci Rep. 2021 Nov 19;11(1):22630
pubmed: 34799659
PLoS One. 2020 Oct 8;15(10):e0240205
pubmed: 33031427
Clin Infect Dis. 2022 May 30;74(10):1776-1785
pubmed: 34383889
AIDS Res Ther. 2022 Jan 14;19(1):3
pubmed: 35031068